Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Fluoroquinolone antimicrobial drugs

Tiffany Chan and Paul E. Bunce
CMAJ May 01, 2017 189 (17) E638; DOI: https://doi.org/10.1503/cmaj.160938
Tiffany Chan
Department of Medicine (Chan, Bunce), University of Toronto; Division of Infectious Diseases (Bunce), University Health Network, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul E. Bunce
Department of Medicine (Chan, Bunce), University of Toronto; Division of Infectious Diseases (Bunce), University Health Network, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Paul.Bunce@uhn.ca
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Fluoroquinolones are antimicrobial drugs with broad-spectrum activity

Fluoroquinolones are bactericidal agents that inhibit DNA synthesis in bacteria. Early fluoroquinolones (e.g., ciprofloxacin) primarily target gram-negative bacteria, including Pseudomonas species. Newer agents (e.g., levofloxacin and moxifloxacin) have expanded coverage against gram-positive bacteria (e.g., Staphylococcus and Streptococcus species), Mycobacterium species and some anaerobes, but have reduced activity against Pseudomonas species.1

Empirical use of fluoroquinolones for many community-acquired infections is not recommended

In 2016, the United States Food and Drug Administration advised that the adverse effects of fluoroquinolones outweighed their benefits for the treatment of acute sinusitis and bronchitis, and uncomplicated urinary tract infections.2 If fluoroquinolones are used empirically, they should be changed to a narrower-spectrum agent after results for susceptibility testing are available.2

Fluoroquinolone use is associated with development of antimicrobial resistance and therapeutic failure

Resistance to fluoroquinolones is found in up to 34% of infections due to Neisseria gonorrhoeae in Canada3 and in 11% of urinary infections due to Escherichia coli in North America.4 Resistance in isolates of Streptococcus pneumoniae remains low (i.e., about 1.2% in Canada).3 Awareness of local resistance patterns is essential because of the variability in rates across regions.

Fluoroquinolones should be prescribed on an individual basis

Fluoroquinolones should be prescribed only for patients requiring broad spectrum antibiotics who have severe β-lactam allergies (e.g., anaphylaxis) or require treatment of organisms resistant to first-line agents. Fluoroquinolones offer a convenient and cost-effective option in patients with deep-seated infections (e.g., osteomyelitis and prostatitis) because of their once- or twice-daily dosing and greater than 90% oral bioavailability.1 Consultation with an infectious disease specialist should be considered when prescribing fluoroquinolones for such complicated infections.

Fluoroquinolones may have serious adverse effects

Severe adverse effects include gastrointestinal complaints (common, up to 10% of cases), QT prolongation that may cause malignant arrhythmias, tendinopathy, diarrhea associated with Clostridium difficile (uncommon, up to 5% of cases), dysglycemia, neuropathy and retinal detachment (uncommon, up to 1% of cases).1,5 Fluoroquinolones should not be given in conjunction with calcium supplements, which decrease their bioavailability, or with other QT-prolonging agents.1

CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. Hooper DC
    . New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000;30:243–54.
    OpenUrlCrossRefPubMed
  2. ↵
    FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; updated 2016. Available: www.fda.gov/Drugs/DrugSafety/ucm500143.htm (accessed 2016 May 27).
  3. ↵
    Canadian Antimicrobial Resistance Surveillance System — report 2016. Ottawa: Public Health Agency of Canada; 2016.
  4. ↵
    1. Karlowsky JA,
    2. Hoban DJ,
    3. DeCorby MR,
    4. et al
    . Fluoroquino-lone-resistant urinary isolates of Escherichia coli from out-patients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study. Antimicrob Agents Chemother 2006;50:2251–4.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Lipsky BA,
    2. Baker CA
    . Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28:352–64.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (17)
CMAJ
Vol. 189, Issue 17
1 May 2017
  • Table of Contents
  • Index by author

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fluoroquinolone antimicrobial drugs
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Fluoroquinolone antimicrobial drugs
Tiffany Chan, Paul E. Bunce
CMAJ May 2017, 189 (17) E638; DOI: 10.1503/cmaj.160938

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Fluoroquinolone antimicrobial drugs
Tiffany Chan, Paul E. Bunce
CMAJ May 2017, 189 (17) E638; DOI: 10.1503/cmaj.160938
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Fluoroquinolones are antimicrobial drugs with broad-spectrum activity
    • Empirical use of fluoroquinolones for many community-acquired infections is not recommended
    • Fluoroquinolone use is associated with development of antimicrobial resistance and therapeutic failure
    • Fluoroquinolones should be prescribed on an individual basis
    • Fluoroquinolones may have serious adverse effects
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Prostatic abscess
  • Relapsing fever in a traveller returning from Senegal
  • Orbital floor fracture
Show more Practice

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire